These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. Onuma Y; Serruys PW; Ormiston JA; Regar E; Webster M; Thuesen L; Dudek D; Veldhof S; Rapoza R EuroIntervention; 2010 Sep; 6(4):447-53. PubMed ID: 20884431 [TBL] [Abstract][Full Text] [Related]
4. Bioresorbable Vascular Scaffolds--Will Promise Become Reality? Byrne RA N Engl J Med; 2015 Nov; 373(20):1969-71. PubMed ID: 26457446 [No Abstract] [Full Text] [Related]
5. Coronary artery aneurysms formation within Everolimus-eluting stents and bioresorbable vascular scaffolds. Lee WC; Chung WJ; Fang HY; Wu CJ Int J Cardiol; 2016 Mar; 206():58-60. PubMed ID: 26774833 [No Abstract] [Full Text] [Related]
6. Angiographic and optical coherence tomography insights into bioresorbable scaffold thrombosis: single-center experience. Karanasos A; Van Mieghem N; van Ditzhuijzen N; Felix C; Daemen J; Autar A; Onuma Y; Kurata M; Diletti R; Valgimigli M; Kauer F; van Beusekom H; de Jaegere P; Zijlstra F; van Geuns RJ; Regar E Circ Cardiovasc Interv; 2015 May; 8(5):. PubMed ID: 25969547 [TBL] [Abstract][Full Text] [Related]
7. Vascular response to bioresorbable polymer sirolimus-eluting stent vs. permanent polymer everolimus-eluting stent at 9-month follow-up: an optical coherence tomography sub-study from the CENTURY II trial. Kuramitsu S; Kazuno Y; Sonoda S; Domei T; Jinnouchi H; Yamaji K; Soga Y; Shirai S; Ando K; Saito S Eur Heart J Cardiovasc Imaging; 2016 Jan; 17(1):34-40. PubMed ID: 26333375 [TBL] [Abstract][Full Text] [Related]
8. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532 [TBL] [Abstract][Full Text] [Related]
9. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. Diletti R; Serruys PW; Farooq V; Sudhir K; Dorange C; Miquel-Hebert K; Veldhof S; Rapoza R; Onuma Y; Garcia-Garcia HM; Chevalier B Am Heart J; 2012 Nov; 164(5):654-63. PubMed ID: 23137495 [TBL] [Abstract][Full Text] [Related]
10. Biodegradable drug-eluting stents: promises and pitfalls. Di Mario C; Ferrante G Lancet; 2008 Mar; 371(9616):873-4. PubMed ID: 18342665 [No Abstract] [Full Text] [Related]
11. Bioresorbable polymer sirolimus-eluting coronary stent compared with permanent polymer everolimus-eluting coronary stent implantation for treatment of small vessel coronary artery disease: CENTURY II trial. Wöhrle J; Markovic S; Rottbauer W; Muramatsu T; Kadota K; Vázquez-González N; Odenstedt J; Serra A; Antoniucci D; Varenne O; Saito S; Wijns W EuroIntervention; 2016 Jun; 12(2):e167-74. PubMed ID: 27290676 [TBL] [Abstract][Full Text] [Related]
14. The ABSORB III Trial: Potential New Concepts for Intracranial Atherosclerosis in the Post-SAMMPRIS Era. Aoun RJ; Sattur MG; Panchanathan RS; Bendok BR Neurosurgery; 2016 Feb; 78(2):N19-20. PubMed ID: 26779796 [No Abstract] [Full Text] [Related]
15. A case of true left main bifurcation treated with bioresorbable everolimus-eluting stent v-stenting. Sato K; Latib A; Panoulas VF; Naganuma T; Miyazaki T; Colombo A JACC Cardiovasc Interv; 2014 Aug; 7(8):e103-4. PubMed ID: 25086841 [No Abstract] [Full Text] [Related]
16. Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial. Kufner S; Byrne RA; Valeskini M; Schulz S; Ibrahim T; Hoppmann P; Schneider S; Laugwitz KL; Schunkert H; Kastrati A; EuroIntervention; 2016 Mar; 11(12):1372-9. PubMed ID: 25405657 [TBL] [Abstract][Full Text] [Related]
17. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials. Muramatsu T; Onuma Y; García-García HM; Farooq V; Bourantas CV; Morel MA; Li X; Veldhof S; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW; JACC Cardiovasc Interv; 2013 Mar; 6(3):247-57. PubMed ID: 23517836 [TBL] [Abstract][Full Text] [Related]
18. Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trial. Gogas BD; Serruys PW; Diletti R; Farooq V; Brugaletta S; Radu MD; Heo JH; Onuma Y; van Geuns RJ; Regar E; De Bruyne B; Chevalier B; Thuesen L; Smits PC; Dudek D; Koolen J; Windecker S; Whitbourn R; Miquel-Hebert K; Dorange C; Rapoza R; Garcia-Garcia HM; McClean D; Ormiston JA JACC Cardiovasc Interv; 2012 Jun; 5(6):656-65. PubMed ID: 22721662 [TBL] [Abstract][Full Text] [Related]